<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761302</url>
  </required_header>
  <id_info>
    <org_study_id>A9290220</org_study_id>
    <nct_id>NCT04761302</nct_id>
  </id_info>
  <brief_title>Postoperative Pain Management in Patients Undergoing Intramedullary Nail Fixation After Tibia and Femoral Fractures</brief_title>
  <official_title>Postoperative Pain Management in Patients Undergoing Intramedullary Nail Fixation After Tibia and Femoral Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Puerto Rico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Puerto Rico</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether oral acetaminophen and intravenous&#xD;
      ketorolac are viable alternatives to opioid medication regimens for the pain management of&#xD;
      patients with tibial and femoral shaft fractures treated with intramedullary nailing. This&#xD;
      study will explore an alternative for opioid medications for patients undergoing&#xD;
      intramedullary nailing of tibial and femoral shaft fractures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 14, 2021</start_date>
  <completion_date type="Anticipated">January 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores using numerical rating scale (NRS, 0 to 10)</measure>
    <time_frame>Three to five days</time_frame>
    <description>Pre-operative holding area</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain scores using numerical rating scale (NRS, 0 to 10)</measure>
    <time_frame>Three to five days</time_frame>
    <description>Post-operative 12 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain scores using numerical rating scale (VAS, 0 to 10)</measure>
    <time_frame>Three to five days</time_frame>
    <description>Post-operative 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain scores using numerical rating scale (VAS, 0 to 10)</measure>
    <time_frame>Three to five days</time_frame>
    <description>Post-operative 36 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain scores using numerical rating scale (VAS, 0 to 10)</measure>
    <time_frame>Three to five days</time_frame>
    <description>Post-operative 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to postoperative pain drugs</measure>
    <time_frame>Zero to 72 hours postoperative</time_frame>
    <description>Describe possible drug related complications such as: headache, nausea, vomit, dizziness, pruritus, urinary retention, constipation, gastrointestinal bleeding, cardiovascular complications, respiratory complications, delirium, among others</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Opioid Consumption</measure>
    <time_frame>Zero to 72 hours postoperative</time_frame>
    <description>Recorded postoperative after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>1 to 5 days</time_frame>
    <description>Time from intervention to discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Femur Fracture</condition>
  <condition>Tibial Fractures</condition>
  <arm_group>
    <arm_group_label>Group 1: Intravenous Ketorolac and oral acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will be composed of patients receiving the following standard pain control protocol: ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group. Patients who determine pain to be unbearable and wish to opt out of the non-opioid group will receive may do so.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Intravenous Morphine and oral oxycodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 will be composed of patients receiving the following pain control protocol: morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Use of non-steroid anti-inflammatory drugs (NSAIDS) as an alternative for post-operative pain management after a femur and tibia fracture</intervention_name>
    <description>This is a prospective, single blind, parallel groups, opioid control trial of all patients (total of 150 patients) who suffered tibial and femoral shaft fractures and were treated with intramedullary nailing. Patients will be aleatory assigned to two study groups: Group-1 will receive non-opioid medications, and Group-2 will receive opioid medications. During the inpatient postoperative period, patients will undergo subjective evaluation of pain utilizing a previously validated questionnaire, the Visual Analogue Score (VAS). The first questionnaire will be completed twelve hours after surgery and during subsequent twelve-hour intervals until discharge. Secondary outcomes will include efficiency such as time to gastrointestinal motility, time to weight bearing of affected limb, resumption of ambulation, and length of hospital stay. The evaluation will take approximately 15 minutes to complete each time, we the entire participation time to be 60 minutes.</description>
    <arm_group_label>Group 1: Intravenous Ketorolac and oral acetaminophen</arm_group_label>
    <arm_group_label>Group 2: Intravenous Morphine and oral oxycodone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with tibial and femoral shaft fractures&#xD;
&#xD;
          2. Patients undergoing intramedullary nailing&#xD;
&#xD;
          3. Willing to participate in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic pain disorder (daily use of oral opioids)&#xD;
&#xD;
          2. Allergy or hypersensitivity to non steroid anti-inflammatory drug&#xD;
&#xD;
          3. Impaired renal, cardiac, or hepatic function&#xD;
&#xD;
          4. History of gastrointestinal bleeding or substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis F. Lojo-Sojo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopaedic Surgery Section, University of Puerto Rico Medical Sciences Campus San Juan, Puerto Rico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerardo Olivella, MD, MPH</last_name>
    <phone>7877645095</phone>
    <email>gerardo.olivella@upr.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans Hess Arcelay, MD</last_name>
    <phone>7873655755</phone>
    <email>hans.hess1@upr.edu</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid use</keyword>
  <keyword>Post-operative pain</keyword>
  <keyword>Analgesic use</keyword>
  <keyword>Femur fracture</keyword>
  <keyword>Tibia fracture</keyword>
  <keyword>Intramedullary Nailing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

